Is VKTX a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Viking Therapeutics (VKTX) rests on Lead obesity program (VK2735): VK2735 is a dual GLP-1 and GIP receptor agonist for obesity, now in Phase 3 in both injectable and oral forms. The bear case rests on viking is a clinical-stage biotech with no approved products and no product revenue, so it is highly speculative and potentially binary. Analysts covering it publish targets from $38.00 to $125.00 against a $25.17 price, so even the professionals disagree by 92% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Viking Therapeutics (VKTX) is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Its highest-profile program is VK2735, a dual GLP-1 and GIP receptor agonist for obesity, being developed in both injectable and oral forms, which puts Viking among the most closely watched challengers in the booming weight-loss drug market dominated by Novo Nordisk and Eli Lilly. Viking is also developing VK2809, a thyroid-hormone receptor beta agonist for non-alcoholic steatohepatitis (NASH/MASH), VK0214 for a rare disease (X-linked adrenoleukodystrophy), and VK3019, an amylin receptor agonist. As a clinical-stage company, Viking has no approved products and generates no product revenue, funding itself from cash on its balance sheet. Headquartered in San Diego, California, VKTX is a speculative, binary biotech whose value hinges on clinical-trial outcomes and the eventual commercial path for its lead obesity drug. The late-stage program is now in place. The injectable VANQUISH Phase 3 trials are fully enrolled, with about 4,500 adults in VANQUISH-1 and about 1,000 adults with type 2 diabetes in VANQUISH-2, testing weekly doses over 78 weeks. On October 14, 2026 Viking started SUNRISE, the Phase 3 program for oral VK2735: two 68-week trials of about 560 adults each, one without and one with type 2 diabetes, testing once-daily doses of 27.5 mg, 35 mg and 55 mg against placebo. That follows the Phase 2 VENTURE-Oral study, where 13 weeks of treatment produced mean weight loss of up to 12.2%, with mostly mild or moderate, early gastrointestinal side effects. Running those trials is expensive. Viking lost about $535 million over the twelve months to June 2026, including about $128 million in the second quarter, when its loss of $1.10 per share was narrower than the $1.21 consensus. It held about $502 million of cash with almost no debt at the end of June. The stock closed near $26.17 on October 16, 2026, down about 26% year to date, 25% over one year and 31% over three months, close to its 52-week low of $25.28. Analysts remain bullish: 20 cover it with a strong-buy consensus and a mean target near $94.50, and UBS initiated coverage at buy with a $94 target in October. Third-quarter results are expected around October 28, 2026.
The bull case: what would have to be true for $125.00
The most optimistic published target on VKTX is $125.00, +396.6% from the $25.17 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Lead obesity program (VK2735).
VK2735 is a dual GLP-1 and GIP receptor agonist for obesity, now in Phase 3 in both injectable and oral forms. The injectable VANQUISH-1 and VANQUISH-2 trials are fully enrolled with roughly 5,500 patients combined, and the oral SUNRISE program began in October 2026 after Phase 2 data showed up to 12.2% mean weight loss at 13 weeks. Strong data put Viking among the most-watched challengers to Novo Nordisk and Eli Lilly in a very large obesity-drug market, and an oral option could be a meaningful differentiator if it succeeds.
2. Pipeline breadth in metabolic disease.
Beyond obesity, Viking is developing VK2809, a thyroid-hormone receptor beta agonist for NASH/MASH, a large liver-disease market, VK0214 for the rare disease X-linked adrenoleukodystrophy, and VK3019, an amylin receptor agonist. An oral VK2735 maintenance-dosing trial is also under way. Multiple shots on goal in metabolic and endocrine disorders give the company more than a single binary outcome, though the obesity program dominates the story.
3. Strategic and acquisition optionality.
Successful obesity assets are highly sought after, and large pharma companies have been acquiring or partnering with GLP-1 developers. Viking's data and dual injectable/oral approach make it a frequently mentioned acquisition or partnership candidate, which is part of why the stock reacts sharply to both clinical data and deal speculation.
4. Funding two Phase 3 programs.
With about $502 million of cash at mid-2026 and a trailing net loss of about $535 million, Viking is now spending at a late-stage pace across two large Phase 3 programs. How long that cash lasts, and whether the company raises equity, takes on a partner, or is acquired before data arrive, is one of the main swing factors for shareholders over the next year.
The bear case: what would have to be true for $38.00
The most pessimistic published target is $38.00, +51.0% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Viking Therapeutics is worth if the risks below bite instead of the drivers above.
Viking is a clinical-stage biotech with no approved products and no product revenue, so it is highly speculative and potentially binary. A single disappointing trial readout, safety signal, or regulatory setback for VK2735 could sharply reduce the stock's value. The obesity market is intensely competitive, dominated by Novo Nordisk and Eli Lilly with deep resources and manufacturing scale, and crowded with other entrants. Viking's losses widened sharply as Phase 3 work began (about $535 million over the trailing twelve months against about $502 million of cash), so it may need to raise more capital, diluting shareholders. Manufacturing, commercialization, and pricing all remain unproven. The stock has fallen about 31% in three months to near its 52-week low despite bullish analyst targets, which shows how sentiment can move independently of the pipeline. This is a high-risk position whose outcome depends on clinical and regulatory events outside investors' control.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding VKTX already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on VKTX
20 analysts cover VKTX, with an average target of $94.50 (+275.4% against $25.17) and a split of 19 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the VKTX forecast and price target page.
How is VKTX valued? (as of October 2026)
Snapshot for VKTX as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Product revenue: ~$0 (no approved products)
- Net loss (TTM): ~$535 million; Q2 2026 ~$128 million
- EPS (Q2 2026): -$1.10 vs -$1.21 consensus; Q3 consensus ~-$1.06
- Cash vs debt: ~$502 million cash, ~$4 million debt (June 2026)
- Market cap: ~$3.3 billion at ~$26.17
- Price / book: ~7.5x
- Dividend yield: 0% (no dividend)
- Analyst view: 20 analysts, strong buy consensus, mean target ~$94.50
Viking has no earnings to value on a P/E basis; the stock is priced on the probability-weighted potential of its pipeline, above all VK2735 in obesity, and on acquisition speculation. At about $3.3 billion, the market is valuing two Phase 3 obesity programs at roughly $2.8 billion above cash, while analysts' targets imply far more. Cash runway matters because the annual loss now exceeds the cash balance, so additional fundraising could dilute holders. All figures are approximate and should be verified against current filings.
How do you decide if VKTX is a buy?
Rather than asking whether VKTX is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold VKTX indirectly through an index or sector ETF before adding more.
What would change your mind on VKTX
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Lead obesity program (VK2735) stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: viking is a clinical-stage biotech with no approved products and no product revenue, so it is highly speculative and potentially binary fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the VKTX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about VKTX against your real portfolio and see your actual exposure before deciding.
Investing in Viking Therapeutics with AI
Connect the broker you already use and ask Walnut's AI how VKTX fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is VKTX a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Lead obesity program (VK2735), with product revenue at ~$0 (no approved products). The bear case rests on viking is a clinical-stage biotech with no approved products and no product revenue, so it is highly speculative and potentially binary. Analysts covering it are spread from $38.00 to $125.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell VKTX?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Viking is a clinical-stage biotech with no approved products and no product revenue, so it is highly speculative and potentially binary. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $38.00, +51.0% from the $25.17 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for VKTX?
+
Lead obesity program (VK2735). VK2735 is a dual GLP-1 and GIP receptor agonist for obesity, now in Phase 3 in both injectable and oral forms. The most optimistic analyst target on VKTX is $125.00, +396.6% from the $25.17 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for VKTX?
+
Viking is a clinical-stage biotech with no approved products and no product revenue, so it is highly speculative and potentially binary. A single disappointing trial readout, safety signal, or regulatory setback for VK2735 could sharply reduce the stock's value. The obesity market is intensely competitive, dominated by Novo Nordisk and Eli Lilly with deep resources and manufacturing scale, and crowded with other entrants. Viking's losses widened sharply as Phase 3 work began (about $535 million over the trailing twelve months against about $502 million of cash), so it may need to raise more capital, diluting shareholders. Manufacturing, commercialization, and pricing all remain unproven. The stock has fallen about 31% in three months to near its 52-week low despite bullish analyst targets, which shows how sentiment can move independently of the pipeline. This is a high-risk position whose outcome depends on clinical and regulatory events outside investors' control. The most pessimistic published target is $38.00, +51.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Viking Therapeutics do?
+
Clinical-stage biotech whose value rides on VK2735, its GLP-1/GIP obesity drug; a high-risk, binary bet on trial data.
What would have to change for VKTX to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Lead obesity program (VK2735)) stalling in the reported numbers rather than in the narrative, the risk above (viking is a clinical-stage biotech with no approved products and no product revenue, so it is highly speculative and potentially binary) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What is VKTX's ticker symbol?
+
VKTX, for Viking Therapeutics Inc, listed on Nasdaq. The company is headquartered in San Diego, California, and trades during US market hours at every major US brokerage.
What does Viking Therapeutics do?
+
Viking Therapeutics is a clinical-stage biopharmaceutical company developing treatments for metabolic and endocrine disorders. Its lead program is VK2735, a dual GLP-1/GIP receptor agonist for obesity in injectable and oral forms, both now in Phase 3. It also has VK2809 for NASH/MASH, VK0214 for a rare disease and VK3019, an amylin agonist. It has no approved products yet.
Is VKTX a GLP-1 or weight-loss stock?
+
Yes. Viking's lead drug, VK2735, is a GLP-1/GIP receptor agonist for obesity, which is why VKTX is widely viewed as a weight-loss or GLP-1 stock and a closely watched challenger to Novo Nordisk and Eli Lilly. The drug is in Phase 3 development and not yet approved.
Walnut is informational, not investment advice, and gives no verdict on VKTX. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.
Guides that feature VKTX
VKTX is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.